The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials

Autoimmunity Reviews

Volumn 17, Issue 3, 2018, Pages 215-225

  Li, Guo min ^a,b   Zhao, Jie ^a,b   Li, Bing ^a   Zhang, Xiao fei ^a   Ma, Jian xiong ^a   Ma, Xin long ^a   Liu, Jun ^a  

^a TIANJIN HOSPITAL   (China)

^b NONE

Author keywords

Atorvastatin; Meta analysis; Randomized controlled trial (RCT); Rheumatoid arthritis (RA); Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; DAS28; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LIPID BLOOD LEVEL; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; META ANALYSIS (TOPIC);

ARTHRITIS, RHEUMATOID; ATORVASTATIN CALCIUM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85040610046     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.10.013     Document Type: Review

References (53)

1. Strand, V., Singh, J.A., Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials [J]. Am J Manag Care, 13(Suppl. 9), 2007, S237 (4).
2. Mcinnes, I.B., Schett, G., The pathogenesis of rheumatoid arthritis — NEJM [J]. N Engl J Med, 365(23), 2011, 2205.
3. Alamanos, Y., Drosos, A.A., Epidemiology of adult rheumatoid arthritis [J]. Autoimmun Rev 4:3 (2005), 130–136.
4. Initiative, C., Rheumatoid arthritis classification criteria [J]. Arthritis Rheum 62:9 (2010), 2569–2581 (2010).
5. Athyros, V.G., Papageorgiou, A.A., Athyrou, V.V., et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia [J]. Diabetes Care 25:7 (2002), 1198–1202.
6. Kosinski, M., Kujawski, S.C., Martin, R., et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response [J]. Am J Manag Care 8:3 (2002), 231–240.
7. Smolen, J.S., Aletaha, D., Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges [J]. Nat Rev Rheumatol, 11(5), 2015, 276.
8. Malhotra, H.S., Goa, K.L., Atorvastatin [J]. Drugs 61:12 (2001), 1835–1881.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial [J]. Lancet 360:9326 (2002), 7–22.
10. Adams, S.P., Tsang, M., Wright, J.M., Atorvastatin for lowering lipids [M]. The Cochrane Library, 2015, John Wiley & Sons, Ltd.
11. Tobert, J.A., Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors [J]. Nat Rev Drug Discov 2:7 (2003), 517–526.
12. Ridker, P.M., Rifai, N., Pfeffer, M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein [J]. Circulation 100:3 (1999), 230–235.
13. Libby, P., Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events [J]. Acc Curr J Rev 10:6 (2001), 1959–1965.
14. Kwak, B., Mulhaupt, F., Myit, S., et al. Statins as a newly recognized type of immunomodulator [J]. Nat Med, 6(12), 2000, 1399.
15. Jain, M.K., Ridker, P.M., Anti-inflammatory effects of statins: clinical evidence and basic mechanisms [J]. Nat Rev Drug Discov, 4(12), 2005, 977.
16. Rosenson, R.S., Tangney, C.C., Casey, L.C., Inhibition of proinflammatory cytokine production by pravastatin [J]. Lancet 353:9157 (1999), 983–984.
17. Arnaud, C., Burger, F., Steffens, S., et al. Statins reduce interleukin-6–induced C-reactive protein in human hepatocytes [J]. Arterioscler Thromb Vasc Biol 25:6 (2005), 1231–1236.
18. Moreland, L., Trial of atorvastatin in rheumatoid arthritis [J]. Curr Rheumatol Rep 7:5 (2005), 379–380.
19. Klareskog, L., Hamsten, A., Statins in rheumatoid arthritis—two birds with one stone? [J]. Lancet 363:9426 (2004), 2011–2012.
20. Leung, B.P., Sattar, N., Crilly, A., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis [J]. J Immunol 170:3 (2003), 1524–1530.
21. Paraskevas, K.I., Statin treatment for rheumatoid arthritis: a promising novel indication [J]. Clin Rheumatol 27:3 (2008), 281–287.
22. Yu, Mei, Li, Xiaochun, Guo, Hangyuan, et al. Changes of inflammatory cytokines in patients with rheumatoid arthritis and intervention of atorvastatin [J]. ECG Circ 36:3 (2017), 170–174 (Chinese).
23. Sarabi, Z.S., Saeidi, M.G., Khodashahi, M., et al. Evaluation of the anti-inflammatory effects of atorvastatin on patients with rheumatoid arthritis: a randomized clinical trial [J]. Electron Physician 8:8 (2016), 2700–2706.
24. Mowla, K., Rajai, E., Ghorbani, A., et al. Effect of atorvastatin on the disease activity and severity of rheumatoid arthritis: double-blind randomized controlled trial [J]. J Clin Diagn Res 10:5 (2016), 32–36.
25. Smakotina, S.A., Zelendinova, A.R., Bondareva, I.N., et al. Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases [J]. Ter Arkh 87:9 (2015), 72–76.
26. Mcinnes, I.B., Kim, H.Y., Lee, S.H., et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study [J]. Ann Rheum Dis, 73(1), 2014, 124.
27. Salman, S., Jawad, H.M., Shukur, S., et al. Atorvastatin in treatment of rheumatoid arthritis [J]. Blackwell Publ, 44(17), 2014, 58.
28. Singh, H., Talapatra, P., Mathur, R., Singhania, A., Lather, K., Garg, K., et al. Role of atorvastatin on disease activity of rheumatoid arthritis patients [J]. Blackwell Publ, 108(8), 2013, S30.
29. Semb, A.G., Kvien, T.K., Demicco, D.A., et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease [J]. Atherosclerosis Suppl, 12(9), 2012, 2836.
30. Tang, T.T., Song, Y., Ding, Y.J., et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis [J]. J Lipid Res 52:5 (2011), 1023–1032.
31. Elbarbary, A.M., Hussein, M.S., Rageh, E.M., et al. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis [J]. J Rheumatol, 38(2), 2011, 229.
32. Semb, A.G., Holme, I., Kvien, T.K., et al. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial [J]. Rheumatology 50:2 (2011), 324–329.
33. Sandooghi, M., Zakeri, Z., Almasy, S., et al. A comparative study on atorvastatin versus methotrexate in rheumatoid arthritis in a double blind placebo control trial [J]. Shiraz E Med J 12:4 (2011), 189–195.
34. Nikitina, N.M., Rebrov, A.P., The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia [J]. Kardiologiia 49:9 (2009), 21–26.
35. Charles-Schoeman, C., Khanna, D., Furst, D.E., et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study [J]. J Rheumatol, 34(7), 2007, 1459.
36. Mccarey, D.W., Mcinnes, I.B., Rajan, M., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial [J]. Lancet 363:9426 (2004), 2015–2021.
37. Higgins, J.P., Altman, D.G., Gøtzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials [J]. BMJ, 343, 2011 (oct18 2:d5928-d5928).
38. Dersimonian, R., Laird, N., Meta-analysis in clinical trials [J]. Control Clin Trials 7:3 (1986), 177–188.
39. Cochran, William G., The combination of estimates from different experiments [J]. Biometrics 10:1 (1954), 101–129.
40. Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses [J]. Br Med J 327:7414 (2003), 557–560.
41. Egger, M., Davey Smith, G., Schneider, M., et al. Bias in meta-analysis detected by a simple, graphical test [J]. Br Med J 315:7109 (1997), 629–634.
42. Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias [J]. Biometrics 50:4 (1994), 1088–1101.
43. Gewurz, H., Mold, C., Siegel, J., et al. C-reactive protein and the acute phase response [J]. Adv Intern Med 27 (1982), 345–372.
44. Saadeh, C., Amarillo, T., The erythrocyte sedimentation rate: old and new clinical applications [J]. Women, 4, 1998, 11.
45. Cruickshank, A.M., Fraser, W.D., Burns, H.J.G., et al. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity [J]. Clin Sci 79:2 (1990), 161–165.
46. Holt, I., Cooper, R.G., Hopkins, S.J., Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients[J]. Eur J Clin Invest 21:5 (1991), 479–484.
47. Waetzig, G.H., Seegert, D., Rosenstiel, P., et al. p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease[J]. J Immunol 168:10 (2002), 5342–5351.
48. Zhou, T., Zhou, S.H., Qi, S.S., et al. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome [J]. Clin Chim Acta 368:1 (2006), 168–172.
49. Lewandowski, M., Kornacewicz-Jach, Z., Millo, B., et al. The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value [J]. Cardiol J 15:4 (2008), 357–364.
50. Yangchun Liu, M.D., Qiang Su, M.D., Lang Li, M.D. PhD, Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials [J]. Clin Cardiol, 36(12), 2013, E41.
51. Lodi, S., Evans, S.J.W., Egger, P., et al. Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database [J]. Br J Clin Pharmacol 69:1 (2010), 85–94.
52. Van Lenten, B.J., Hama, S.Y., de Beer, F.C., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. [J]. J Clin Invest 96:6 (1995), 2758–2767.
53. Lin, C.H., Hsu, K.W., Chen, C.H., et al. Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats [J]. Biochem Pharmacol 142:1 (2017), 216–228.